What is Xeris Biopharma's backlog?

Xeris Biopharma reported $6.20M of remaining performance obligations at 30 Sep 2026 and up 24% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.01.

Xeris Biopharma (XERS) backlog: remaining performance obligations

How much revenue Xeris Biopharma already has under contract, how fast it converts, and who it is with.

Data as of 7 Nov 2026.

Open the interactive Backlog view Xeris Biopharma competitor analysis

Xeris Biopharma reported $6.20M of remaining performance obligations at 30 Sep 2026 and up 24% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.01.
Net new backlog added in the latest quarter: $1.20M.
By backlog size it ranks 521st among US filers the cockpit tracks.

Xeris Biopharma backlog history

Remaining performance obligations at each quarter end (bars) against trailing twelve-month revenue (line).

Amounts in USD. Source: SEC XBRL filings.
Quarter end	Backlog (RPO)	TTM revenue	Customer prepayments
30 Sep 2026	$6.20M	$368M	n/a
30 Jun 2026	$5.00M	$335M	n/a
31 Dec 2025	$4.80M	$292M	n/a

Questions

What is Xeris Biopharma's backlog?: Xeris Biopharma reported $6.20M of remaining performance obligations at 30 Sep 2026 and up 24% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.01.

About these numbers

Remaining performance obligations (RPO) are revenue a company has contracted but not yet recognised, as reported in its SEC filings (XBRL tag RevenueRemainingPerformanceObligation). Coverage = backlog ÷ trailing twelve-month revenue. Book-to-bill = (change in backlog + revenue) ÷ revenue. Conversion = revenue recognised ÷ the backlog at the start of each quarter, summed over four quarters. Counterparty values come from company filings and releases.